Why is the ECOSPOR III study Important?
The leading risk factor for Clostridium difficile infection (CDI) is a prior history of taking antibiotics. Exposure to antibiotics can harm the good bacteria in the gut that make up our microbiome. These beneficial bacteria protect us from harmful invaders, like C. difficile, which can cause diarrhea. Although CDI treatment is available, many patients continue to have recurrent infections because their microbiome doesn't recover.
To qualify for this study, a person must:
All study-related visits, tests, and medication will be provided to participants at no cost. Reimbursement for time and travel may be provided.
The PRISM 3 clinical research study is for patients who have had a recurrence of Clostridium difficile infection (CDI or C. diff). The study will evaluate the safety and effectiveness of the study drug to prevent recurrence of CDI compared against placebo.
If you have Crohn's consider taking part in the Etro Study.
WHY PARTICIPATE IN A CLINCIAL TRIAL?
You may get expert medical care from leading specialists and nurses throughout the study
You remain in control of your level of participation
You contribute to scientific understanding of Crohn's
You might qualify for a clinical study for a new medication for nausea and the symptoms of gastropareses.
Qualified participants will receive study-related care and study medication at no charge as well as receive reimbursement for time and participation.
A high percentage of gastroparesis patients have difficulty with a variety of symptoms from abdominal pain to nausea and vomiting.
Researchers in the United States are looking for up to 150 adults diagnosed with idiopathic or diabetic gastroparesis who
Have you been clinically diagnosed with CHRONIC PANCREATITIS?
Do you have ABDOMINAL PAIN associated with your disease?
You may be eligible to participate in a clinical research study, being conducted in your local area, evaluating the effects of an investigational drug on pain related to chronic pancreatitis.
What is the study about?
FIGARO 302 is a clinical research study designed to explore an investigational drug-SHP647-for participants with moderate-to-severe ulcerative colitis (UC) who have responded inadequately to conventional treatment.